These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27826212)

  • 1. A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine.
    Kwok YH; Swift JE; Gazerani P; Rolan P
    J Pain Res; 2016; 9():899-907. PubMed ID: 27826212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial Attenuation With Ibudilast in the Treatment of Medication Overuse Headache: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial of Efficacy and Safety.
    Johnson JL; Kwok YH; Sumracki NM; Swift JE; Hutchinson MR; Johnson K; Williams DB; Tuke J; Rolan PE
    Headache; 2015 Oct; 55(9):1192-208. PubMed ID: 26367865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
    Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
    Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy of a double-blind, placebo-controlled, randomized study for repetitive sphenopalatine blockade with bupivacaine vs. saline with the Tx360 device for treatment of chronic migraine.
    Cady RK; Saper J; Dexter K; Cady RJ; Manley HR
    Headache; 2015 Apr; 55(4):529-42. PubMed ID: 25828648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures.
    Silberstein S; Lipton R; Dodick D; Freitag F; Mathew N; Brandes J; Bigal M; Ascher S; Morein J; Wright P; Greenberg S; Hulihan J
    Headache; 2009 Sep; 49(8):1153-62. PubMed ID: 19719543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
    MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S
    Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
    Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
    Tronvik E; Stovner LJ; Helde G; Sand T; Bovim G
    JAMA; 2003 Jan; 289(1):65-9. PubMed ID: 12503978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Controlled Pilot Trial of Behavioral Insomnia Treatment for Chronic Migraine With Comorbid Insomnia.
    Smitherman TA; Walters AB; Davis RE; Ambrose CE; Roland M; Houle TT; Rains JC
    Headache; 2016 Feb; 56(2):276-91. PubMed ID: 26813845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment.
    Silberstein SD; Rapoport AM; Loupe PS; Aycardi E; McDonald M; Yang R; Bigal ME
    Headache; 2019 Mar; 59(3):383-393. PubMed ID: 30450545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
    Bigal ME; Edvinsson L; Rapoport AM; Lipton RB; Spierings EL; Diener HC; Burstein R; Loupe PS; Ma Y; Yang R; Silberstein SD
    Lancet Neurol; 2015 Nov; 14(11):1091-100. PubMed ID: 26432181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study.
    Silberstein SD; Hulihan J; Karim MR; Wu SC; Jordan D; Karvois D; Kamin M
    Clin Ther; 2006 Jul; 28(7):1002-11. PubMed ID: 16990078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers.
    Cooper ZD; Johnson KW; Pavlicova M; Glass A; Vosburg SK; Sullivan MA; Manubay JM; Martinez DM; Jones JD; Saccone PA; Comer SD
    Addict Biol; 2016 Jul; 21(4):895-903. PubMed ID: 25975386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Intravenous Methamphetamine Administration During Ibudilast Treatment.
    DeYoung DZ; Heinzerling KG; Swanson AN; Tsuang J; Furst BA; Yi Y; Wu YN; Moody DE; Andrenyak DM; Shoptaw SJ
    J Clin Psychopharmacol; 2016 Aug; 36(4):347-54. PubMed ID: 27269956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of exogenous ketone bodies for preventive treatment of migraine: A study protocol for a single-centred, randomised, placebo-controlled, double-blind crossover trial.
    Gross E; Putananickal N; Orsini AL; Schmidt S; Vogt DR; Cichon S; Sandor P; Fischer D
    Trials; 2019 Jan; 20(1):61. PubMed ID: 30654835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occipital nerve block for the short-term preventive treatment of migraine: A randomized, double-blinded, placebo-controlled study.
    Dilli E; Halker R; Vargas B; Hentz J; Radam T; Rogers R; Dodick D
    Cephalalgia; 2015 Oct; 35(11):959-68. PubMed ID: 25505035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.